This year C5’s 2015 Pharma & Biotech Patent Litigation Conference will focus on the practical solutions to the current challenges facing pharma companies, patent attorneys, legal practitioners and regulatory officers. Participants will be presented with specific strategies used by leading industry experts in dealing with patent litigation challenges in 2014.
Oppositions & Litigation is one of Plougmann Vingtoft’s core skills and our highly skilled IP attorneys have outstanding records of achievement in representing large international companies before the Opposition Division of the European Patent Office as well as the Boards of Appeal.
Friday 20th of March, Head of the our Opposition and Litigation team, Kim Wagner, and our European Patent Attorney, Henrik Skødt, will be sharing their thoughts on how policies in clinical trials affect patentability. Here, they will tell about their experience working on the controversial Bayer v. Hexal case concerning public prior use of clinical trials at EPO (T 7/07).
The main topics are:
- The established case law and public prior use in clinical trials
- Bayer v. Hexal (Yasmin®): a new standard?
- Informed consent and trials contract: best practices
- How to do clinical trials without destroying novelty
- The circumstances underlying T 7/07 (Yasmin®)
Please do not hesitate to contact either Kim Wagner (kiw@pv.eu) or Henrik Skødt (hes@pv.eu) if you want to arrange a meeting with us during the conference.
Also bare in mind that we offer clients and contacts a 10% discount off the standard conference registration fee.
Have a look at the programme for the conference below.
